Dr. Jan Chemnitz is a co-founder of PROVIREX. Since its inception, he has been one of the company’s CEOs and has focused on its transition from start-up to a Series A funded biotech company. He is also responsible for building up a collaborative network with other biotech companies as well as academia and implementing the ongoing academic clinical study “HIVCure” into the company’s future strategy.

He studied biochemistry/molecular biology in Jena. After his PhD at the Leibniz Institute of Virology in Hamburg, he joined the Hauber group as a postdoc and was involved in the development of the recombinase technology from the beginning; he has now been working in the field of HIV cure strategies for 20 years.